Skip to main content

01.12.2015 | Research article | Ausgabe 1/2016 Open Access

BMC Public Health 1/2016

The acceptability and cost of a home-based chlamydia retesting strategy: findings from the REACT randomised controlled trial

BMC Public Health > Ausgabe 1/2016
K. S. Smith, J. M. Kaldor, J. S. Hocking, M. S. Jamil, A. M. McNulty, P. Read, C. S. Bradshaw, M. Y. Chen, C. K. Fairley, H. Wand, K. Worthington, S. Blake, V. Knight, W. Rawlinson, M. Saville, S. N. Tabrizi, S. M. Garland, B. Donovan, R. Guy
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12889-016-2727-4) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JMK, JSH, AMM, PR, CSB, MYC, CKF, HW, WR, MS, SNT, SMG, KSS, BD and RG contributed to the original study design. RG conceived of the study and directed the analysis. KW, SB, VK and KSS participated in study implementation and data collection. MSJ, RG and KSS performed the analysis. KSS and RG drafted the initial manuscript. All authors reviewed and revised drafts, contributed to the interpretation of the results and read and approved the final manuscript.



Chlamydia retesting three months after treatment is recommended to detect reinfections, but retesting rates are typically low. The REACT (retest after Chlamydia trachomatis) randomised trial demonstrated that home-based retesting using postal home-collection kits and SMS reminders, resulted in substantial improvements in retesting rates in women, heterosexual men and men who have sex with men (MSM), with detection of more repeat positive tests compared with SMS reminder alone. In the context of this trial, the acceptability of the home-based strategy was evaluated and the costs of the two strategies were compared.


REACT participants (200 women, 200 heterosexual men, 200 MSM) were asked to complete an online survey that included home-testing acceptability and preferred methods of retesting. The demographics, sexual behaviour and acceptability of home collection were compared between those preferring home-testing versus clinic-based retesting or no preference, using a chi-square test. The costs to the health system of the clinic-based and home retesting strategies and the cost per infection for each were also compared.


Overall 445/600 (74 %) participants completed the survey; 236/445 from the home-testing arm, and 141 of these (60 %) retested at home. The majority of home arm retesters were comfortable having the kit posted to their home (86 %); found it easy to follow the instructions and collect the specimens (96 %); were confident they had collected the specimens correctly (90 %); and reported no problems (70 %). Most (65 %) preferred home retesting, 21 % had no preference and 14 % preferred clinic retesting. Comparing those with a preference for home testing to those who didn’t, there were significant differences in being comfortable having a kit sent to their home (p = 0.045); not having been diagnosed with chlamydia previously (p = 0.030); and living with friends (p = 0.034). The overall cost for the home retest pathway was $154 (AUD), compared to $169 for the clinic-based retesting pathway and the cost per repeat infection detected was $1409 vs $3133.


Among individuals initially diagnosed with chlamydia in a sexual health clinic setting, home-based retesting was shown to be highly acceptable, preferred by most participants, and cost-efficient. However some clients preferred clinic-based testing, often due to confidentiality concerns in their home environment. Both options should be provided to maximise retesting rates.

Trial registration

The trial was registered with the Australia New Zealand Clinical Trials Registry on September 9, 2011: ACTRN12611000968​976.
Additional file 1: REACT Survey. (PDF 379 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

BMC Public Health 1/2016 Zur Ausgabe